Small Molecule c-jun-N-terminal Kinase (JNK) Inhibitors Protect Dopaminergic Neurons in a Model of Parkinson's Disease.

There are currently no drugs to treat neurodegeneration in Parkinson's disease (PD) and all existing medications only treat symptoms, lose efficacy over time, and produce untoward side effects. In the current work, we report the first highly selective, orally bioavailable, c-jun-N-terminal kinase (JNK) inhibitor for protection of dopaminergic neurons in vitro and in vivo. At 300 nM this compound showed statistically significant protection of primary dopaminergic neurons exposed to 1-methyl-4-phenylpyridinium (MPP(+)), had pharmacokinetic properties in rodents consistent with twice daily (b.i.d.) dosing, and was orally efficacious at 30 mg/kg in a mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson's disease. Moreover, a dose-dependent target modulation of c-jun phosphorylation served as a biomarker for demonstrating on-target inhibition of JNK as the mechanism of action for this compound. Collectively these results suggest that this JNK inhibitor could be a promising therapeutic neuroprotective agent in the treatment of Parkinson's disease.

[1]  David S. Park,et al.  Inhibition of Calpains Prevents Neuronal and Behavioral Deficits in an MPTP Mouse Model of Parkinson's Disease , 2003, The Journal of Neuroscience.

[2]  P. Lograsso,et al.  Structure-Activity Relationships and X-ray Structures Describing the Selectivity of Aminopyrazole Inhibitors for c-Jun N-terminal Kinase 3 (JNK3) over p38* , 2009, Journal of Biological Chemistry.

[3]  T. Dawson,et al.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[4]  P. Lograsso,et al.  Synthesis, biological evaluation, X-ray structure, and pharmacokinetics of aminopyrimidine c-jun-N-terminal kinase (JNK) inhibitors. , 2010, Journal of medicinal chemistry.

[5]  Ming-tao Li,et al.  SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson’s disease , 2004, Neuroscience Research.

[6]  A. Lang,et al.  Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.

[7]  Ted M. Dawson,et al.  Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.

[8]  Y. Oh,et al.  A distinct death mechanism is induced by 1-methyl-4-phenylpyridinium or by 6-hydroxydopamine in cultured rat cortical neurons: degradation and dephosphorylation of tau , 2003, Neuroscience Letters.

[9]  Werner Poewe,et al.  A double-blind, delayed-start trial of rasagiline in Parkinson's disease. , 2009, The New England journal of medicine.

[10]  Pasko Rakic,et al.  JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[11]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[12]  M. Schwarzschild,et al.  The parkinsonian neurotoxin, MPP+ induces phosphorylated c-Jun in dopaminergric neurons of mesencephalic cultures. , 2001, Parkinsonism & related disorders.

[13]  T. Joh,et al.  A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo , 2004, Neurobiology of Disease.

[14]  J. Bilsland,et al.  Caspase Inhibitors Attenuate 1-Methyl-4-Phenylpyridinium Toxicity in Primary Cultures of Mesencephalic Dopaminergic Neurons , 2002, The Journal of Neuroscience.

[15]  M. Beal,et al.  Celastrol protects against MPTP‐ and 3‐nitropropionic acid‐induced neurotoxicity , 2005, Journal of neurochemistry.

[16]  M. Leist,et al.  ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF-alpha. , 1997, Immunology letters.

[17]  M. Emborg Evaluation of animal models of Parkinson's disease for neuroprotective strategies , 2004, Journal of Neuroscience Methods.

[18]  R. Burke,et al.  Mutant LRRK2R1441G BAC transgenic mice recapitulate cardinal features of Parkinson's disease , 2009, Nature Neuroscience.

[19]  P. Lograsso,et al.  Synthesis and SAR of piperazine amides as novel c-jun N-terminal kinase (JNK) inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[20]  J. Uney,et al.  Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Przedborski,et al.  Protocol for the MPTP mouse model of Parkinson's disease , 2007, Nature Protocols.

[22]  Jos Prickaerts,et al.  Modeling Parkinson's Disease in Rats: An Evaluation of 6-OHDA Lesions of the Nigrostriatal Pathway , 2002, Experimental Neurology.

[23]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[24]  Denis M. Bayada,et al.  Polar Molecular Surface as a Dominating Determinant for Oral Absorption and Brain Penetration of Drugs , 1999, Pharmaceutical Research.

[25]  Y. Martin,et al.  A bioavailability score. , 2005, Journal of medicinal chemistry.

[26]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[27]  R. Obach,et al.  Validated assays for human cytochrome P450 activities. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[28]  A. Lang,et al.  Parkinson's disease. Second of two parts. , 1998, The New England journal of medicine.

[29]  Anders Björklund,et al.  Characterization of Behavioral and Neurodegenerative Changes Following Partial Lesions of the Nigrostriatal Dopamine System Induced by Intrastriatal 6-Hydroxydopamine in the Rat , 1998, Experimental Neurology.

[30]  Jun Chen,et al.  Apoptosis inducing factor mediates caspase‐independent 1‐methyl‐4‐phenylpyridinium toxicity in dopaminergic cells , 2005, Journal of neurochemistry.

[31]  Dong-Kug Choi,et al.  Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.

[32]  P. Lograsso,et al.  3,5-Disubstituted quinolines as novel c-Jun N-terminal kinase inhibitors. , 2007, Bioorganic & medicinal chemistry letters.